BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 26497907)

  • 1. Adjusting Cyclophosphamide Dose in Obese Patients with Lymphoma Is Safe and Yields Favorable Outcomes after Autologous Hematopoietic Cell Transplantation.
    Bachanova V; Rogosheske J; Shanley R; Burns LJ; Smith SM; Weisdorf DJ; Brunstein CG
    Biol Blood Marrow Transplant; 2016 Mar; 22(3):571-4. PubMed ID: 26497907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Dose Adjustment Strategies for Obesity in High-dose Cyclophosphamide Among Adult Hematopoietic Cell Transplantation Recipients: Pharmacokinetic Analysis.
    Takahashi T; Jaber MM; Al-Kofahi M; Weisdorf D; Brunstein C; Bachanova V; Brundage RC; Jacobson PA; Kirstein MN
    Transplant Cell Ther; 2022 Dec; 28(12):845.e1-845.e8. PubMed ID: 36167308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Busulfan, cyclophosphamide, and etoposide as high-dose conditioning regimen in patients with malignant lymphoma.
    Hänel M; Kröger N; Sonnenberg S; Bornhäuser M; Krüger W; Kroschinsky F; Hänel A; Metzner B; Birkmann J; Schmid B; Hoffknecht MM; Fiedler F; Ehninger G; Zander AR
    Ann Hematol; 2002 Feb; 81(2):96-102. PubMed ID: 11907790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body irradiation plus Cy as conditioning regimen--a report from the acute leukemia working party of the European group for blood and marrow transplantation.
    Nagler A; Rocha V; Labopin M; Unal A; Ben Othman T; Campos A; Volin L; Poire X; Aljurf M; Masszi T; Socie G; Sengelov H; Michallet M; Passweg J; Veelken H; Yakoub-Agha I; Shimoni A; Mohty M
    J Clin Oncol; 2013 Oct; 31(28):3549-56. PubMed ID: 23980086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Total body irradiation compared with BEAM: Long-term outcomes of peripheral blood autologous stem cell transplantation for non-Hodgkin's lymphoma.
    Liu HW; Seftel MD; Rubinger M; Szwajcer D; Demers A; Nugent Z; Schroeder G; Butler JB; Cooke A
    Int J Radiat Oncol Biol Phys; 2010 Oct; 78(2):513-20. PubMed ID: 20137862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of 2 Carmustine-Containing Regimens in the Rituximab Era: Excellent Outcomes Even in Poor-Risk Patients.
    Caimi PF; William BM; Silva Rondon CH; Fu P; Cooper BW; Campagnaro EL; Gerson SL; Reese-Koc J; Fox R; Creger RJ; de Lima M; Lazarus HM
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):1926-31. PubMed ID: 26087475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Total body irradiation and cyclophosphamide plus antithymocyte globulin regimen is well tolerated and promotes stable engraftment as a preparative regimen before T cell-replete haploidentical transplantation for acute leukemia.
    Fu H; Xu L; Liu D; Liu K; Zhang X; Chen H; Chen Y; Han W; Wang Y; Wang J; Wang F; Huang X
    Biol Blood Marrow Transplant; 2014 Aug; 20(8):1176-82. PubMed ID: 24747336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autologous transplantation for relapsed non-Hodgkin's lymphoma using intravenous busulfan and cyclophosphamide as conditioning regimen: a single center experience.
    Escalón MP; Stefanovic A; Venkatraman A; Pereira D; Santos ES; Goodman M; Byrnes JJ; Fernandez HF
    Bone Marrow Transplant; 2009 Jul; 44(2):89-96. PubMed ID: 19169287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of total body irradiation vs busulfan in combination with cyclophosphamide as conditioning for unrelated stem cell transplantation in CML patients.
    Kröger N; Zabelina T; Krüger W; Renges H; Stute N; Kabisch H; Jaburg N; Löliger C; Krüll A; Zander AR
    Bone Marrow Transplant; 2001 Feb; 27(4):349-54. PubMed ID: 11313663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma.
    Law LY; Horning SJ; Wong RM; Johnston LJ; Laport GG; Lowsky R; Shizuru JA; Blume KG; Negrin RS; Stockerl-Goldstein KE
    Biol Blood Marrow Transplant; 2006 Jul; 12(7):703-11. PubMed ID: 16785059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autologous stem cell transplantation for non-Hodgkin's lymphoma: comparison of radiation-based and chemotherapy-only preparative regimens.
    Gutierrez-Delgado F; Maloney DG; Press OW; Golden J; Holmberg LA; Maziarz RT; Hooper H; Buckner CD; Appelbaum FR; Bensinger WI
    Bone Marrow Transplant; 2001 Sep; 28(5):455-61. PubMed ID: 11593318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and toxicity of high-dose cyclophosphamide in obese versus non-obese patients receiving allogeneic hematopoietic stem cell transplant.
    Hunter MR; Sabo RT; McCarty JM; Newland AM
    J Oncol Pharm Pract; 2016 Feb; 22(1):54-9. PubMed ID: 25245037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytochrome P450 2B6*5 Increases Relapse after Cyclophosphamide-Containing Conditioning and Autologous Transplantation for Lymphoma.
    Bachanova V; Shanley R; Malik F; Chauhan L; Lamba V; Weisdorf DJ; Burns LJ; Lamba JK
    Biol Blood Marrow Transplant; 2015 May; 21(5):944-8. PubMed ID: 25677220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma.
    Rodriguez R; Nademanee A; Ruel N; Smith E; Krishnan A; Popplewell L; Zain J; Patane K; Kogut N; Nakamura R; Sarkodee-Adoo C; Forman SJ
    Biol Blood Marrow Transplant; 2006 Dec; 12(12):1326-34. PubMed ID: 17162215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of total body irradiation, cyclophosphamide, and cytarabine as a conditioning regimen for allogeneic hematopoietic stem cell transplantation in patients with acute lymphoblastic leukemia.
    Mori T; Aisa Y; Kato J; Yamane A; Nakazato T; Shigematsu N; Okamoto S
    Am J Hematol; 2012 Apr; 87(4):349-53. PubMed ID: 22290459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose fractionated total-body irradiation, etoposide and cyclophosphamide for treatment of malignant lymphoma: comparison of autologous bone marrow and peripheral blood stem cells.
    Brunvand MW; Bensinger WI; Soll E; Weaver CH; Rowley SD; Appelbaum FR; Lilleby K; Clift RA; Gooley TA; Press OW; Fefer A; Storb R; Sanders JE; Martin PL; Chauncey T; Maziarz RT; Zuckerman N; Montgomery P; Dorn R; Weiden PL; Demirer T; Holmberg LA; Schiffman K; McSweeney PA; Buckner CD
    Bone Marrow Transplant; 1996 Jul; 18(1):131-41. PubMed ID: 8832006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose fractionated total-body irradiation, etoposide, and cyclophosphamide followed by autologous stem-cell support in patients with malignant lymphoma.
    Weaver CH; Petersen FB; Appelbaum FR; Bensinger WI; Press O; Martin P; Sandmaier B; Deeg HJ; Hansen JA; Brunvand M
    J Clin Oncol; 1994 Dec; 12(12):2559-66. PubMed ID: 7989929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of cyclophosphamide and total body irradiation with etoposide and total body irradiation as conditioning regimens for patients undergoing sibling allografting for acute lymphoblastic leukemia in first or second complete remission.
    Marks DI; Forman SJ; Blume KG; Pérez WS; Weisdorf DJ; Keating A; Gale RP; Cairo MS; Copelan EA; Horan JT; Lazarus HM; Litzow MR; McCarthy PL; Schultz KR; Smith DD; Trigg ME; Zhang MJ; Horowitz MM
    Biol Blood Marrow Transplant; 2006 Apr; 12(4):438-53. PubMed ID: 16545728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Favorable outcomes in elderly patients undergoing high-dose therapy and autologous stem cell transplantation for non-Hodgkin lymphoma.
    Dahi PB; Tamari R; Devlin SM; Maloy M; Bhatt V; Scordo M; Goldberg J; Zelenetz AD; Hamlin PA; Matasar MJ; Maragulia J; Giralt SA; Perales MA; Moskowitz CH; Sauter CS
    Biol Blood Marrow Transplant; 2014 Dec; 20(12):2004-9. PubMed ID: 25175794
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Busulfan and cyclophosphamide (Bu/Cy) as a preparative regimen for autologous stem cell transplantation in patients with non-Hodgkin lymphoma: a single-institution experience.
    Ulrickson M; Aldridge J; Kim HT; Hochberg EP; Hammerman P; Dube C; Attar E; Ballen KK; Dey BR; McAfee SL; Spitzer TR; Chen YB
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1447-54. PubMed ID: 19822305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.